Research programme: leukotriene B4 receptor antagonists - Dong Wha/Procter & GambleAlternative Names: DW-1352
Latest Information Update: 01 Dec 2009
At a glance
- Originator Dong Wha Pharmaceutical
- Mechanism of Action Bone resorption factor inhibitors; Leukotriene B4 receptor antagonists; Osteogenesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 04 Jul 2007 Preclinical development for Osteoporosis in South Korea (PO)